TauRx Pharmaceuticals Stock

TauRx Pharmaceuticals is a life sciences company developing drugs and diagnostics for neurodegenerative diseases.

Sign up today and learn more about TauRx Pharmaceuticals Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About TauRx Pharmaceuticals Stock

TauRx Therapeutics Ltd was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases based on an entirely new approach which targets aggregates of abnormal fibres of Tau protein that form inside nerve cells in the brain. The TauRx team have since discovered that LMTX™ could also have beneficial effects in several other neurodegenerative diseases associated with Tau pathology, as well as other protein aggregation disorders including Parkinson’s, Huntington’s and Frontotemporal Dementia (Pick’s Disease). While TauRx headquarters are in Singapore, its primary research facilities are in Aberdeen, Scotland.

Funding History

November 2012$112M
March 2013$10.5M
October 2015$135M
November 2022$119M

Management

Chief Business Officer (Aberdeen)

Tim Earle

Chief Development Officer (Aberdeen)

John K S Cheung

Chief Medical Officer (Aberdeen)

Jiri Hardlund

Chief Scientific Officer (Aberdeen)

Charles Harrington

Co-Founder, Chairman and Chief Executive (Aberdeen)

Claude Wischik

Technical Head (Aberdeen)

John Storey

Global Logistics and Support Lead (Aberdeen)

Diane Downie

Finance Director (Singapore)

Hwang Hong Wei

Member of the Scientific Advisory Board

Howard Feldman

Member of the Board of Directors

George Chia

Head Of Commercial and Communications

Rebecca Andersen

Member of the Scientific Advisory Board

Giovanni Frisoni

Alternate Director

Goh Lee Sian

Global Project Lead

Lolwa Fawzy

Member of the Board of Directors

Paul Cheng

Member of the Board of Directors

Sushilan Vasoo

Member of the Scientific Advisory Board

Lon Schneider

Director

Toby O’Connor

Member of the Scientific Advisory Board

Gordon Wilcock

Managing Director

Seng Way

Global Project Lead

Tadeusz Januszewski

Global Project Lead, Phase 1 and 2 studies (Aberdeen)

Zulfiqar Haider

Member of the Scientific Advisory Board

Serge Gauthier

Deputy Chairman of the Board of Directors

Tay Choon

Alternate Director

Frederick Stevenson-Robb

Chief Operating Officer and Chief Business Officer

Glenn Corr

Member of the Board of Directors

Stephen Logan

Deputy Legal Counsel (Aberdeen)

Marcus Wischik

Member of the Board of Directors

Tan Han

Alternate Director

Goh Chung Meng

Member of the Board of Directors

Seng Way

Executive Chairman of the Board of Directors

Claude Wischik

Member of the Board of Directors

Tan Thay

Alternate Director

Joan Tan

Alternate Director

Woon Yoke Sun

Alternate Director

Loh Yin Sze

Member of the Board of Observer

Franz Theuring

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo